Clinical trials: Covid-19 Patients
Covid19, Corona Virus Infection
Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS
The world is currently experiencing a coronavirus (CoV-2) pandemic. A new (SARS)-CoV infection epidemic began in Wuhan, Hubei, China, in late 2019; originally called 2019- nCoV the virus is now known as SARSCoV- 2 and the disease…
- Conditions
- Covid19, Corona Virus Infection, ARDS, Aviptadil
- Trial name
- NCT04536350
- Testing
- Aviptadil 67μg
- Where
- 2 sites in Switzerland
- Volunteers
- 83 people
- Sponsor
- Prof. Dr. Jörg Leuppi
COVID-19
Study of SHEN26 Capsule in Patients With Mild to Moderate COVID-19
This is a multicenter, randomized, double-blind, placebo-parallel-controlled phase II clinical trial. It is designed to evaluate the efficacy, safety, tolerability, and pharmacokinetic (PK) profile of SHEN26 capsules in Chinese…
- Trial name
- NCT05676073
- Testing
- SHEN26 dose 1, SHEN26 dose 2
- Where
- 4 sites in China
- Volunteers
- 91 people
- Sponsor
- Shenzhen Kexing Pharmaceutical Co., Ltd.
COVID-19, Lymphocytopenia
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort)
Comparison of the effects of CYT107 vs Placebo administered by intra-muscular route (IM) at 10μg/kg twice a week for three weeks on immune reconstitution of lymphopenic COVID-19 patients
- Trial name
- ILIAD-7-BRA (NCT04927169)
- Testing
- Interleukin-7
- Where
- 6 sites in Brazil
- Volunteers
- 4 people
- Sponsor
- Revimmune
Neuroimaging, COVID-19
Neuroimaging Findings in Patients With COVID-19
This study aimed to discuss the neuroimaging findings and indications, epidemiological data, laboratory values, and the relationship of these variables with mortality in patients with COVID-19.
- Trial name
- NCT04734223
- Testing
- Neuroimaging Findings in Patients With COVID-19
- Where
- Turkey (Türkiye)
- Volunteers
- 436 people, healthy volunteers welcome
- Sponsor
- Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
Acute Respiratory Distress Syndrome Due to SARS-CoV-2 Infection (Severe COVID19)
A Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE)
The study is a prospective, randomized, placebo-controlled, single-blind phase 2 clinical study of the efficacy and safety of AMY-101, a potent C3 inhibitor, for the management of patients with ARDS caused by SARS-CoV-2…
- Trial name
- SAVE (NCT04395456)
- Testing
- AMY-101, WFI 5% glucose
- Volunteers
- 144 people
- Sponsor
- Amyndas Pharmaceuticals S.A.
Covid-19, SARS-CoV 2
Baricitinib Compared to Standard Therapy in Patients With COVID-19
There is urgent need of an effective therapy for Covid-19. To date, the best treatment of SARS-CoV-2 infection is unknown. Baricitinib has been identified as potential treatment for 2019-nCoV acute respiratory disease, because of…
- Conditions
- Covid-19, SARS-CoV 2, SARS Pneumonia
- Trial name
- BARICIVID-19 (NCT04393051)
- Testing
- Baricitinib Oral Tablet
- Where
- Italy
- Volunteers
- 126 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
COVID-19 Pneumonia
Study to Evaluate the Efficacy and Safety of EG-009A Compared to DEX in Patients With COVID-19 Pneumonia
To study signals of efficacy and safety of a currently available dosage form (IM) of EG-009A in reducing the severity of respiratory disease in patients hospitalized with SARS-CoV-2 virus.
- Trial name
- NCT04561180
- Testing
- EG-009A, Standard of Care, Dexamethasone
- Sponsor
- Evergreen Therapeutics, Inc.
Oncology
Remote COVID-19 Symptom Tracking for Cancer Patients at Home During the Pandemic
This project will evaluate the benefit of an automated home symptom monitoring system, Symptom Care at Home, to track COVID-19 symptoms, provide instructions to reduce COVID-19 exposure, and reduce cancer symptom severity during…
- Trial name
- NCT04464486
- Testing
- SCH Intervention
- Where
- United States
- Volunteers
- 301 people
- Sponsor
- University of Utah
Coronavirus
COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial)
Vitamin D is a secosteroid hormone produced by the skin during Summer exposure to UVB rays. Hypovitaminosis D is common in Winter (October to March) at Northern latitudes above 20 degrees North, and from April to September at…
- Trial name
- NCT04344041
- Testing
- cholecalciferol 200,000 IU, cholecalciferol 50,000 IU
- Where
- 9 sites in France
- Volunteers
- 260 people
- Sponsor
- University Hospital, Angers
Covid19
Immunohematology in COVID-19 Patients: A Hospital-based Retrospective Cohort Study
This is a hospital-based retrospective cohort study and the Immunohematologic characteristics of COVID-19 patients will be investigated systematically.
- Trial name
- NCT04932954
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- LI YAN
COVID-19 Pandemic
NanoMn®_COVID-19 A Prospective, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blind Trial to Evaluate the Clinical Efficacy of NanoManganese® on Top of Standard of Care, in Adult Patients With Moderate to Severe Coronavirus Disease 2019 (COVID-19)
This is a prospective, multicenter, randomized (3:1), placebo- controlled, parallel-group, double-blind trial. Patients will be randomized into two arms of treatment: Placebo + SoC (N=30) NanoManganese® + SoC (N=90) Patients will…
- Trial name
- NCT05451654
- Testing
- Experimental drug
- Where
- Brazil
- Volunteers
- 7 people
- Sponsor
- Medesis Pharma SA
Cancer, Covid19
CCP Cancer UK Companion Study
Currently, there is extremely limited information regarding the risks posed by SARS-CoV-2 to patients with cancer. This study aims to understand the presentation, management and outcomes of patients with cancer.
- Trial name
- NCT04603105
- Where
- United Kingdom
- Volunteers
- 9,000 people
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
Myeloproliferative Disease, COVID - 19
Autoantibodies Against Type I Interferon in Patients Affected With Ph-negative Myeloproliferative Neoplasms (MPN-IFN Study)
The classic Ph-negative myeloproliferative neoplasms (MPN) are a group of clonal hematopoietic disorders caused by a dysregulated JAK/STAT signal transduction because of acquired somatic mutations of JAK2, CALR or MPL genes.
- Trial name
- NCT07204366
- Where
- Italy
- Volunteers
- 219 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Post ICU Rehabilitation
Use of RDS MultiSense® in Post-ICU Patients in the COVID-19 Era
In this clinical study, the investigators will compare vital parameters measurements obtained using continuous data from reference monitors and continuous wireless MultiSense® monitoring patch in 60 post-ICU (Intensive Care Unit)…
- Trial name
- MONIREA (NCT04661423)
- Testing
- Remote Automated Monitoring System
- Where
- 2 sites in France
- Volunteers
- 60 people
- Sponsor
- IHU Strasbourg
Acute Respiratory Distress Syndrome, COVID19 Infection
Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection
It is a multicenter, national, randomized 1:1 ratio, controlled, parallel, open study. Patients with severe ARDS-CoVid19 will be included in the trial within the first 24 hours.
- Trial name
- SEVO-COVID19 (NCT04359862)
- Testing
- Sevoflurane, Propofol
- Where
- 5 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
COVID-19
Cardiac Biomarkers and Mortality in Critically Ill Patients With SARS-CoV-2 (COVID-19)
Objective: To assess the prognostic value of high-sensitive cardiac troponin T (hs-cTnT) and N-terminal pro brain natriuretic peptide (NT-proBNP) at ICU admission in patients with coronavirus disease 2019 (COVID-19).
- Trial name
- COROBIOCHIC (NCT04641988)
- Where
- France
- Volunteers
- 111 people
- Sponsor
- University Hospital, Montpellier
Corona Virus Infection, Pregnancy; Infection
THE RELATIONSHIP OF CRP/ALBUMIN RATIO LEVEL AND PROGNOSIS IN PREGNANT COVID-19 PATIENTS
The CRP/albumin ratio (CAR) is a recently defined parameter which represents the ratio of a positive acute phase reactant to a negative acute phase reactant.
- Trial name
- NCT05242172
- Testing
- CRP/Albumin ratio
- Where
- Turkey (Türkiye)
- Volunteers
- 127 people
- Sponsor
- Adiyaman University Research Hospital
2019 Novel Coronavirus
The Potential Use of Inhaled Hydroxychloroquine for the Treatment of COVID-19 in Cancer Patients
This is a pilot, randomized, single-center, parallel group, open-label controlled study to evaluate the feasibility, safety, efficacy, and pharmacokinetics of nebulized HCQ01 plus Standard of Care (SOC) versus SOC alone in…
- Trial name
- NCT04731051
- Testing
- HCQ01, standard of care (SOC) for COVID-19
- Where
- Jordan
- Sponsor
- King Hussein Cancer Center
COVID-19
Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients
This open label, randomized, controlled, investigator-initiated, multi-centre trial aims to establish metabolic improvements in COVID-19 subjects by dietary supplementation with cofactors N-acetylcysteine, L-carnitine tartrate…
- Trial name
- NCT04573153
- Testing
- Hydroxychloroquine + Metabolic cofactor supplementation, Hydroxychloroquine + Sorbitol
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- ScandiBio Therapeutics AB
History of Cardiovascular Disease Treated With RAS Blockers and With SARS-CoV-2 Infection
ACE Inhibitors or ARBs Discontinuation in Context of COVID-19 Pandemic
Since December 2019, a novel coronavirus called SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has caused an international outbreak of respiratory illness described as COVID-19.
- Trial name
- ACORES-2 (NCT04329195)
- Testing
- 1: discontinuation of RAS blocker therapy, 2: continuation of RAS blocker therapy
- Where
- France
- Volunteers
- 44 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.